AstraZeneca's Ultomiris treatment gets good results from Phase 3 trial
(Alliance News) - AstraZeneca PLC on Thursday said phase 3 trial results for its Ultomiris treatment showed a "significant" reduction in the risk of relapse in adults with neuromyelitis optica spectrum disorder. Read More